Rosivo closes seed-round paving the path for commercialization of patented cartilage implant technology

December 20, 2021

Rosivo LLC announces it has successfully closed a seed fundraising round for an undisclosed sum from a private investment firm. This funding will enable the company to bring their patented cartilage implant technology to market. 

Rosivo develops biologically-derived therapeutics that incorporate performance-enhancing refinements while maintaining the beneficial intrinsic qualities of biological source materials. The first product being commercialized, Cartesse™, is an implant for the facial reconstruction market. Cartesse™ is Rosivo’s platform for cartilage-derived implants with enhanced stability and biocompatibility. Future applications for this platform technology include joint, intervertebral disc, meniscal, tracheal, and TMJ cartilage repairs. Rosivo’s technology has worldwide market potential with granted patents in N. America, Europe, S. America, and Asia. 

The close of this seed financing round signals just the latest achievement for Rosivo following the 2018 Utah Innovation Award for most innovative medical device. Founder and CEO, Eran Rosines Ph.D., adds, “This is an exciting time for Rosivo. First, we will address the need for cartilage-derived implants in facial reconstruction and then we will address the need for cartilage-derived implants in prolonging active lifestyles.” 

Many indications exist in which biomaterial therapies could provide improved outcomes while possessing a faster route to market and significantly reduced cost compared to cell-based therapies. Rosivo aims to develop refined biomaterial therapies to treat these indications. 

For more information, please visit Rosivo at http://www.rosivo.com or see contact info below.

CONTACT
Eran Rosines, PhD
801-893-1406
info@rosivo.com